Loading organizations...
§ Private Profile · Fremont, CA, USA
Life sciences company developing precision proteomics for ultra-high sensitivity protein detection in early disease detection.
Based in Fremont, California, Alamar Biosciences develops precision proteomics technologies and automated laboratory instruments for ultra-high sensitivity protein detection. The business-to-business company provides biopharmaceutical and academic researchers with its proprietary ARGO HT systems and NULISA assay panels to facilitate the early detection of cancer, Alzheimer's, and various inflammatory diseases. Operating with approximately 140 employees, the life sciences technology provider has raised over $250 million in total venture funding to date. This capitalization includes a $100 million Series C financing round completed in February 2024 to support the commercial launch of its high-throughput proteomics platforms and related research services. The enterprise is backed by a syndicate of institutional investors including Sands Capital, Illumina Ventures, Qiming Venture Partners, and Cormorant Asset Management. Alamar Biosciences was founded in 2018 by Yuling Luo, Steve Chen, and Yiyuan Yin.
Alamar Biosciences has raised $274.0M across 4 funding rounds.
Alamar Biosciences has raised $274.0M in total across 4 funding rounds.
Alamar Biosciences has raised $274.0M across 4 funding rounds. Most recently, it raised $50.0M Other Equity in January 2026.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Jan 11, 2026 | $50M Venture Round | — | Braidwell, Illumina Ventures, Sands Capital, T. Rowe Price Associates | Announced |
| Feb 1, 2024 | $130M Series C | IAN Ratcliffe | Forbion, Qiming Venture Partners | Announced |
| Sep 1, 2021 | $80M Series B | Sherpa Healthcare Partners | Forbion, Illumina Ventures, Qiming Venture Partners, Morningside Ventures, Samsara BioCapital | Announced |
| May 1, 2020 | $14M Series A | — | Forbion, Qiming Venture Partners | Announced |
Alamar Biosciences is a Fremont, California-based life sciences company founded in 2020 that develops the NULISA platform for precision proteomics, enabling ultra-sensitive detection of protein biomarkers from minimal sample volumes like one microliter of plasma.[1][3][5] The platform serves academic researchers, biotech firms, and clinical developers focused on early disease detection, particularly for cancer, Alzheimer's, and inflammatory conditions, by solving key limitations in traditional immunoassays—such as poor sensitivity, high background noise, and limited multiplexing—through DNA-barcoded antibodies and sequential capture-release methods that achieve attomolar detection limits and 10,000-fold signal-to-noise improvements.[1][2][3] Growth momentum includes a $128 million oversubscribed Series C in 2024 (part of $204 million total funding), commercial launches of the ARGO HT automated system and NULISAseq Inflammation Panel 250, and recent products like the NULISAqpcr Custom Assay Development Kit in February 2025, with plans to expand commercialization, customer support, and IVD versions like ARGO DX for Alzheimer's diagnostics.[3][4]
Alamar Biosciences was founded in 2020 by Yuling Luo, PhD (Chairman & CEO), Steve Chen, PhD (COO), Yiyuan Yin, PhD (VP of Technology), with Xiao-Jun Ma, PhD as CTO and Tod White, JD as CFO/CBO.[1][5] The idea emerged from the founders' prior success at Advanced Cell Diagnostics (ACD), where they pioneered RNAscope, the gold standard in spatial genomics by maximizing signal-to-noise ratios; they applied these insights plus genomics advances to reinvent proteomics for liquid biopsy and multiplexed protein profiling.[5] Early traction built on this expertise, with rapid development of NULISA technology, securing ADDF funding for ARGO DX in Alzheimer's research, and launching commercial products like ARGO HT, which automates assays with under 30 minutes hands-on time.[2][3]
Alamar stands out in proteomics through:
Alamar rides the precision proteomics wave, aligning with booming demand for non-invasive liquid biopsies amid advances in genomics and multi-omics integration for early detection of diseases like cancer and neurodegeneration.[1][3][5] Timing is ideal as blood-based biomarkers for Alzheimer's transition from research to clinical use—decades of validation now meet NULISA's sensitivity gap-filling capabilities—while market forces like aging populations, personalized medicine pushes, and post-genomics proteomics hype (e.g., via NGS synergies) favor scalable platforms.[2][3] The company influences the ecosystem by accelerating biomarker discovery for pharma/biotech, enabling IVD tests, and standardizing high-throughput proteomics, potentially transforming diagnostics from reactive to proactive.[2][3]
Alamar is poised to dominate precision proteomics commercialization, leveraging Series C funds for team expansion, menu growth (e.g., more panels, IVDs like ARGO DX), and market penetration in research-to-clinic pipelines.[3] Trends like AI-driven multi-omics, single-cell proteomics standardization, and regulatory nods for blood tests will propel growth, with influence evolving from RUO innovator to diagnostics leader—unlocking the proteome's full potential for earliest disease detection, much like their RNAscope reshaped genomics.[2][3][5]
Alamar Biosciences has raised $274.0M in total across 4 funding rounds.
Alamar Biosciences's investors include Braidwell, Illumina Ventures, Sands Capital, T. Rowe Price Associates, Ian Ratcliffe, Forbion, Qiming Venture Partners, Sherpa Healthcare Partners, Morningside Ventures, Samsara BioCapital.